ERBB2 and breast cancer: For postmenopausal patients with HR-positive, HER2-negative metastatic or recurrent breast cancer without life-threatening visceral metastatic diseases [5], endocrine treatment is usually recommended over chemotherapy for systemic therapy to improve disease control and prolong survival, because it has similar efficacy with fewer side effects [6].